Samantha Semenkow
Stock Analyst at Citi
(3.43)
# 2,264
Out of 4,453 analysts
206
Total ratings
50%
Success rate
3.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Samantha Semenkow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SABS SAB Biotherapeutics | Reiterated: Buy | $11 | $3.84 | +186.46% | 2 | Jun 15, 2026 | |
| CGEM Cullinan Therapeutics | Reiterated: Buy | $33 | $17.65 | +86.97% | 2 | Jun 10, 2026 | |
| ROIV Roivant Sciences | Reiterated: Buy | $35 → $42 | $34.01 | +23.49% | 5 | May 21, 2026 | |
| NKTR Nektar Therapeutics | Maintained: Buy | $151 | $64.84 | +132.88% | 9 | May 13, 2026 | |
| BEAM Beam Therapeutics | Maintained: Buy | $68 | $33.90 | +100.59% | 15 | May 13, 2026 | |
| ARGX argenx SE | Reiterated: Buy | $1,152 | $852.50 | +35.13% | 19 | May 12, 2026 | |
| CPRX Catalyst Pharmaceuticals | Downgraded: Hold | $35 → $32 | $31.42 | +0.25% | 12 | May 7, 2026 | |
| SYRE Spyre Therapeutics | Rated: Buy | $64 → $97 | $86.24 | +12.48% | 3 | May 6, 2026 | |
| WVE Wave Life Sciences | Rated: Buy | $30 → $24 | $5.95 | +303.36% | 4 | May 1, 2026 | |
| ALLO Allogene Therapeutics | Rated: Buy | $4 | $2.05 | +95.12% | 6 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 → $17 | $14.96 | +13.64% | 6 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $46 | $36.28 | +26.79% | 4 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $3.68 | +198.91% | 6 | Mar 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $3.63 | +285.67% | 17 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $136 → $142 | $107.55 | +32.03% | 2 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $6 | $20.00 | -70.00% | 9 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $100 | $48.16 | +107.64% | 5 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 → $52 | $22.83 | +127.77% | 9 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $3.28 | +265.85% | 14 | Mar 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $5 → $4.25 | $3.12 | +36.22% | 8 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $3.03 | +230.03% | 11 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $58 → $57 | $38.22 | +49.14% | 15 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 → $5 | $2.80 | n/a | 9 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $6 → $4 | $24.54 | n/a | 8 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.7 → $0.75 | $0.00001 | n/a | 3 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $130 | $18.37 | n/a | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $16 → $7 | $6.19 | n/a | 2 | Jul 21, 2021 |
SAB Biotherapeutics
Jun 15, 2026
Reiterated: Buy
Price Target: $11
Current: $3.84
Upside: +186.46%
Cullinan Therapeutics
Jun 10, 2026
Reiterated: Buy
Price Target: $33
Current: $17.65
Upside: +86.97%
Roivant Sciences
May 21, 2026
Reiterated: Buy
Price Target: $35 → $42
Current: $34.01
Upside: +23.49%
Nektar Therapeutics
May 13, 2026
Maintained: Buy
Price Target: $151
Current: $64.84
Upside: +132.88%
Beam Therapeutics
May 13, 2026
Maintained: Buy
Price Target: $68
Current: $33.90
Upside: +100.59%
argenx SE
May 12, 2026
Reiterated: Buy
Price Target: $1,152
Current: $852.50
Upside: +35.13%
Catalyst Pharmaceuticals
May 7, 2026
Downgraded: Hold
Price Target: $35 → $32
Current: $31.42
Upside: +0.25%
Spyre Therapeutics
May 6, 2026
Rated: Buy
Price Target: $64 → $97
Current: $86.24
Upside: +12.48%
Wave Life Sciences
May 1, 2026
Rated: Buy
Price Target: $30 → $24
Current: $5.95
Upside: +303.36%
Allogene Therapeutics
Apr 9, 2026
Rated: Buy
Price Target: $4
Current: $2.05
Upside: +95.12%
Apr 2, 2026
Maintained: Buy
Price Target: $14 → $17
Current: $14.96
Upside: +13.64%
Mar 31, 2026
Reiterated: Buy
Price Target: $46
Current: $36.28
Upside: +26.79%
Mar 23, 2026
Reiterated: Buy
Price Target: $11
Current: $3.68
Upside: +198.91%
Mar 20, 2026
Reiterated: Buy
Price Target: $14
Current: $3.63
Upside: +285.67%
Mar 20, 2026
Rated: Buy
Price Target: $136 → $142
Current: $107.55
Upside: +32.03%
Mar 20, 2026
Maintained: Sell
Price Target: $6
Current: $20.00
Upside: -70.00%
Mar 16, 2026
Reiterated: Buy
Price Target: $100
Current: $48.16
Upside: +107.64%
Mar 10, 2026
Maintained: Buy
Price Target: $15 → $52
Current: $22.83
Upside: +127.77%
Mar 4, 2026
Maintained: Buy
Price Target: $12
Current: $3.28
Upside: +265.85%
Nov 11, 2025
Maintained: Hold
Price Target: $5 → $4.25
Current: $3.12
Upside: +36.22%
Oct 10, 2025
Reiterated: Buy
Price Target: $10
Current: $3.03
Upside: +230.03%
Aug 12, 2025
Maintained: Buy
Price Target: $58 → $57
Current: $38.22
Upside: +49.14%
Mar 6, 2025
Maintained: Buy
Price Target: $15 → $5
Current: $2.80
Upside: n/a
Jun 3, 2024
Initiated Coverage: Buy
Price Target: $6 → $4
Current: $24.54
Upside: n/a
May 18, 2023
Maintained: Hold
Price Target: $1.7 → $0.75
Current: $0.00001
Upside: n/a
May 11, 2023
Rated: Buy
Price Target: $130
Current: $18.37
Upside: n/a
Jul 21, 2021
Maintained: Buy
Price Target: $16 → $7
Current: $6.19
Upside: n/a